Gene Transfer

Endostatin Coding Mutes Tumor Growth In Murine Model

Published in Gene Therapy Weekly, August 16th, 2001

by Sonia Nichols, senior medical writer - Members of a research team at the U.S. National Institutes of Health have developed a retroviral vector that transfers genetic coding for endostatin production in vivo, enabling engrafted mice to produce enough of the protein to inhibit tumor growth, they report.

In previous and current human trials, endostatin therapy has been administered via daily injections and infusion pumps. "Difficulties with the stability, manufacture, and long-term administration of recombinant anti-angiogenic proteins have prompted investigators to use gene therapy to generate these proteins in vivo," explained Andrew L. Feldman and colleagues,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-08-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry